Drotrecogin Alfa (Activated) Injection
Last Updated: October 26, 2011
Products Affected - Description
Xigris, Eli Lilly and Company
5 mg vial (NDC 00002-7561-01)
20 mg vial (NDC 00002-7559-01)
Reason for the Shortage
- Lilly discontinued Xigris in October, 2011 due to failure of showing survival benefit in the PROWESS-SHOCK trial. Details of the Xigris withdrawal are available online.
- Do not start any new patients on Xigris and discontinue treatment in patients currently receiving Xigris. Return all unused product to place of purchase.
- Lilly was the only manufacturer of drotrecogin alfa.
Estimated Resupply Dates
Eli Lilly and Company discontinued Xigris in October, 2011.
- Alcohol Dehydrated Injection (Ethanol) — Resolved
- Allopurinol Injection — Resolved
- Amifostine Injection — Resolved
- Azathioprine Injection — No Longer Available — No Commercially Available Preparations
- Colchicine Tablets — Resolved
- Dexrazoxane Injection — Current
- Foscarnet Injection — Resolved
- Leucovorin Calcium Injection — Current
- Levocarnitine Injection — Resolved
- Mechlorethamine Hydrochloride Injection — Resolved
- Metyrosine Capsules — Resolved
- Octreotide Injection — Current
- Phenylephrine 2.5% and 10% Ophthalmic Solution — Resolved
- Sodium Fluoride Oral Drops — Resolved
- Surgical Lubricant — Resolved
- Tiopronin Tablets — Resolved
- Trace Elements Injection — Resolved
- Zinc Injection — Resolved
October 26, 2011, University of Utah, Drug Information Service. Copyright 2011, Drug Information Service, University of Utah, Salt Lake City, UT.